-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 7, Chutian Technology rose rapidly in the intraday market, with an increase of more than 2% within 5 minutes.
As of 13:05, it was reported at 25.
50 yuan, with a turnover of 288 million yuan and a turnover rate of 2.
19%
.
On the news of the pharmaceutical equipment industry (photo source: Pharmaceutical Network), on January 6, Chutian Technology issued an announcement saying that the company reviewed and approved the "Regulations on Granting Partially Reserved Restricted Stocks to Incentive Objects" on January 5, 2022.
Proposal, determining that the reserved grant date of restricted stocks is January 5, 2022, and 635,000 restricted stocks are reserved for granting, and the reserved grant price is 10.
00 yuan per share
.
Restricted stock refers to a special stock granted by a listed company to employees who need incentives according to the conditions set by the company
.
Only when the holder's working years or performance goals meet the conditions stipulated in the equity incentive plan, the holder can trade the restricted stock and obtain income from it
.
Chutian Technology's performance in 2021 is outstanding
.
According to the third quarterly report of 2021, the company achieved operating income of 3.
682 billion yuan in the first three quarters, a year-on-year increase of 67.
24%; net profit of 401 million yuan, a year-on-year increase of 723.
53%, which has doubled the net profit for the whole year of 2020
.
Among them, in the third quarter, Chutian Technology achieved revenue of 1.
291 billion yuan, a year-on-year increase of 57.
9%, and net profit of 165 million yuan, a year-on-year increase of 413.
91%, maintaining a high growth trend
.
According to data from Oriental Fortune, the scheduled disclosure time of Chutian Technology’s 2021 annual report is April 22, 2022
.
Up to now, 7 institutions including Zheshang Securities, CITIC Securities, Southwest Securities and Guosen Securities have made profit forecasts for Chutian Technology in 2021.
It is estimated that Chutian Technology's net profit in 2021 will be between 447.
0 million and 509.
0 million yuan.
, which will double from 201 million yuan in 2020
.
It is worth mentioning that while Chutian Technology handed over a dazzling transcript in 2021, the company's stock price has also risen
.
As of the close on December 31, 2021, Chutian Technology closed at 26.
07 yuan, an increase of 136.
97% from the daily close of 11.
00 yuan on December 31, 2020
.
At present, the company's total market value is 14.
698 billion yuan
.
A few days ago, Zheshang Securities conducted research on Chutian Technology and released a research report, pointing out that Chutian Technology is based on its technological advantages in filling and post-packaging equipment, and actively expands front-end reactor equipment, liquid dispensing and chromatography equipment, etc.
, to fully grasp the epidemic situation.
This is conducive to the company's horizontal (category expansion) and vertical (consumables, fillers, etc.
) expansion of biopharmaceutical equipment
.
In addition, the company strengthened its international layout through the acquisition of Romaco, and established companies such as Chutian Robot and Chutian Huaxing to strengthen intelligent manufacturing collaboration.
Therefore, the agency is optimistic about the company's domestic and foreign market development space for upgrading products, and gives an "overweight" rating
.
From the perspective of the industry background, China's pharmaceutical equipment industry is ushering in a new round of opportunities
.
On the one hand, due to the impact of the epidemic, the delivery time of imported pharmaceutical products has been delayed, the strength of domestic pharmaceutical equipment has been continuously improved and gradually recognized by pharmaceutical companies, and the pace of import substitution is accelerating; on the other hand, due to favorable policies, talents, capital and other multiple factors Factors resonate, the biopharmaceutical industry develops rapidly, the commercialization process continues to accelerate, and the demand for high-end pharmaceutical equipment continues to expand
.
In this context, domestic pharmaceutical machine companies with innovative R&D capabilities and rich technical experience are more likely to undertake development opportunities
.
On January 7, in addition to Chutian Technology, Tofflon rose slightly by 0.
92%.
As of 13:05, it reported 45.
10 yuan, with a turnover of 130 million yuan and a turnover rate of 0.
68%; Canaan Technology also rose rapidly during the session, 5 It rose by more than 2% within minutes.
As of 13:05, the stock reported 18.
72 yuan, with a turnover of 681 million yuan and a turnover rate of 16.
49%
.
As of 13:05, it was reported at 25.
50 yuan, with a turnover of 288 million yuan and a turnover rate of 2.
19%
.
On the news of the pharmaceutical equipment industry (photo source: Pharmaceutical Network), on January 6, Chutian Technology issued an announcement saying that the company reviewed and approved the "Regulations on Granting Partially Reserved Restricted Stocks to Incentive Objects" on January 5, 2022.
Proposal, determining that the reserved grant date of restricted stocks is January 5, 2022, and 635,000 restricted stocks are reserved for granting, and the reserved grant price is 10.
00 yuan per share
.
Restricted stock refers to a special stock granted by a listed company to employees who need incentives according to the conditions set by the company
.
Only when the holder's working years or performance goals meet the conditions stipulated in the equity incentive plan, the holder can trade the restricted stock and obtain income from it
.
Chutian Technology's performance in 2021 is outstanding
.
According to the third quarterly report of 2021, the company achieved operating income of 3.
682 billion yuan in the first three quarters, a year-on-year increase of 67.
24%; net profit of 401 million yuan, a year-on-year increase of 723.
53%, which has doubled the net profit for the whole year of 2020
.
Among them, in the third quarter, Chutian Technology achieved revenue of 1.
291 billion yuan, a year-on-year increase of 57.
9%, and net profit of 165 million yuan, a year-on-year increase of 413.
91%, maintaining a high growth trend
.
According to data from Oriental Fortune, the scheduled disclosure time of Chutian Technology’s 2021 annual report is April 22, 2022
.
Up to now, 7 institutions including Zheshang Securities, CITIC Securities, Southwest Securities and Guosen Securities have made profit forecasts for Chutian Technology in 2021.
It is estimated that Chutian Technology's net profit in 2021 will be between 447.
0 million and 509.
0 million yuan.
, which will double from 201 million yuan in 2020
.
It is worth mentioning that while Chutian Technology handed over a dazzling transcript in 2021, the company's stock price has also risen
.
As of the close on December 31, 2021, Chutian Technology closed at 26.
07 yuan, an increase of 136.
97% from the daily close of 11.
00 yuan on December 31, 2020
.
At present, the company's total market value is 14.
698 billion yuan
.
A few days ago, Zheshang Securities conducted research on Chutian Technology and released a research report, pointing out that Chutian Technology is based on its technological advantages in filling and post-packaging equipment, and actively expands front-end reactor equipment, liquid dispensing and chromatography equipment, etc.
, to fully grasp the epidemic situation.
This is conducive to the company's horizontal (category expansion) and vertical (consumables, fillers, etc.
) expansion of biopharmaceutical equipment
.
In addition, the company strengthened its international layout through the acquisition of Romaco, and established companies such as Chutian Robot and Chutian Huaxing to strengthen intelligent manufacturing collaboration.
Therefore, the agency is optimistic about the company's domestic and foreign market development space for upgrading products, and gives an "overweight" rating
.
From the perspective of the industry background, China's pharmaceutical equipment industry is ushering in a new round of opportunities
.
On the one hand, due to the impact of the epidemic, the delivery time of imported pharmaceutical products has been delayed, the strength of domestic pharmaceutical equipment has been continuously improved and gradually recognized by pharmaceutical companies, and the pace of import substitution is accelerating; on the other hand, due to favorable policies, talents, capital and other multiple factors Factors resonate, the biopharmaceutical industry develops rapidly, the commercialization process continues to accelerate, and the demand for high-end pharmaceutical equipment continues to expand
.
In this context, domestic pharmaceutical machine companies with innovative R&D capabilities and rich technical experience are more likely to undertake development opportunities
.
On January 7, in addition to Chutian Technology, Tofflon rose slightly by 0.
92%.
As of 13:05, it reported 45.
10 yuan, with a turnover of 130 million yuan and a turnover rate of 0.
68%; Canaan Technology also rose rapidly during the session, 5 It rose by more than 2% within minutes.
As of 13:05, the stock reported 18.
72 yuan, with a turnover of 681 million yuan and a turnover rate of 16.
49%
.
